NCT01142401 2023-11-27
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
Clinical Trials
69 trialsNCT01420926 2023-02-28
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT02440464 2023-01-04
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2 Completed
NCT00114738 2022-10-10
EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01078454 2022-02-01
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
National Cancer Institute (NCI)
Phase 3 Completed
NCT01109004 2021-12-09
BMT CTN 0702
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT01381692 2021-10-04
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00381940 2021-03-24
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00061932 2021-02-02
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
National Cancer Institute (NCI)
Phase 2 Completed
NCT01445405 2019-12-17
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00011778 2019-12-12
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00023712 2019-07-30
Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02208037 2019-01-23
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
National Heart, Lung, and Blood Institute (NHLBI)
Phase 2 Completed
NCT00104871 2018-12-19
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00553644 2018-10-30
Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00703664 2018-08-07
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00666588 2018-05-22
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01711528 2018-05-11
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01016730 2018-02-20
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00093756 2017-12-07
Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00362882 2017-12-05
Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00873093 2017-01-27
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00023764 2015-12-08
Bortezomib in Treating Patients With Lymphoproliferative Disorders
National Cancer Institute (NCI)
Phase 2 Completed
NCT00082966 2015-12-04
Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00108069 2015-11-05
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00021216 2015-04-15
Bortezomib in Treating Children With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00383474 2015-04-15
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
National Cancer Institute (NCI)
Phase 1 Completed
NCT00082784 2014-12-23
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
National Cancer Institute (NCI)
Phase 1 Completed
NCT00703300 2014-11-07
Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00083226 2014-10-30
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00433537 2014-10-30
Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00742625 2014-09-12
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00118144 2014-08-21
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00103259 2014-05-23
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
National Cancer Institute (NCI)
Phase 2 Completed
NCT00641706 2014-05-14
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT00937495 2014-05-14
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00227513 2014-02-24
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00091117 2013-12-16
Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT00317811 2013-11-06
Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00052689 2013-10-08
Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00068315 2013-09-30
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00316940 2013-09-20
Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00994500 2013-07-02
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00068289 2013-06-24
Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00072150 2013-06-05
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00077467 2013-06-05
Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00030368 2013-06-04
Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00077441 2013-06-04
Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)
National Cancer Institute (NCI)
Phase 2 Completed
NCT00118183 2013-06-04
Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00045695 2013-05-17
Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia
National Cancer Institute (NCI)
Phase 2 Completed